Patients Biosimilars: Unlocking access, closing the cost divide Every day, countless Americans are forced to choose between meeting basic needs such as food, housing, or transportation and paying for their medications.
News Germany will reimburse haemophilia gene therapy Hemgenix Germany has agreed to reimburse CSL Behring's haemophilia B gene therapy Hemgenix with a 'unique' outcomes-based payment model.
News First drug backed for NHS use in untreated Hodgkin lymphoma Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated late-stage Hodgkin lymphoma.
News Pharma furious as UK Statutory Scheme rebate rate soars The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Market Access Overcoming barriers for global CGT adoption Cell and gene therapies (CGT) have emerged as the next big thing in medicine, holding the power to deliver cures where none previously existed.
News 'Trust gap' is holding back AI in healthcare The potential for AI to help tackle bottlenecks in healthcare is being held back by patient scepticism and doctor concerns about bias and liability.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.